Asociación Española
de Gastroenterología
Esófago-Estómago-Duodeno

Pilar García Iglesias
Coordinador

El grupo de trabajo de Esófago-Estómago-Duodeno (EED) fue constituido en 1999 y desde entonces agrupa a los socios de AEG interesados en la fisiología y las enfermedades de los órganos mencionados, y recoge algunas otras patologías gastroenterológicas que pueden afectar a tramos más distales del tubo digestivo.


The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)
2021 36
Revista
Antibiotics (Basel).
Número de registro del estudio
PMID: 34439015

 The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)

María Caldas  1 , Ángeles Pérez-Aisa  2 , Bojan Tepes  3 , Alma Keco-Huerga  4 , Luis Bujanda  5 , Alfredo J Lucendo  6 , Luis Rodrigo  7 , Dino Vaira  8 , Luis Fernández-Salazar  9 , Jose M Huguet  10 , Jorge Pérez-Lasala  11 , Natasa Brglez Jurecic  12 , Galina Fadeenko  13 , Jesús Barrio  14 , Miguel Areia  15 , Juan Ortuño  16 , Rinaldo Pellicano  17 , Marcis Leja  18 , Javier Molina-Infante  19 , Pavel Bogomolov  20 , Sergey Alekseenko  21 , Manuel Domínguez-Cajal  22 , Judith Gómez-Camarero  23 , Vassiliki Ntouli  24 , Samuel J Martínez-Domínguez  25 , Rafael Ruiz-Zorrilla  26 , Oscar Núñez  27 , Aiman Silkanovna Sarsenbaeva  28 , Pedro Almela  29 , Perminder Phull  30 , Marta Espada  1 , Ignasi Puig  31 , Olga P Nyssen  1 , Francis Mégraud  32 , Colm O'Morain  33 , Javier P Gisbert  1 , the Hp-EuReg Investigators


Antibiotics (Basel). 2021 Aug 11;10(8):965. doi: 10.3390/antibiotics10080965.


Abstract

Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1-1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59-0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4-2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3-5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.

Keywords: Helicobacter pylori; statins; treatment.